Auburn University veterinary school researchers have designed a novel vaccine platform for intracellular pathogens such as malaria and tuberculosis. Both humans and animals can benefit from vaccines based on this research, but developing the veterinary vaccine first is most efficient, according to lead researcher and veterinarian Bernhard Kaltenboeck. "The veterinary route is going to produce a much quicker return on a lower investment, versus human vaccine, that takes much longer to produce a return and is a much higher investment," Kaltenboeck said.

Related Summaries